InflaRx Set to Showcase Innovations at Healthcare Conference

Author: Dylan Bailey Updated: 10-21-2025 07:21 AM

InflaRx to Participate in Healthcare Innovation Conference

InflaRx N.V. (Nasdaq: IFRX), a leading biopharmaceutical company focused on groundbreaking anti-inflammatory treatments, has confirmed its participation in the upcoming Guggenheim Securities 2nd Annual Healthcare Innovation Conference. This significant event will take place from November 10 to November 12. On November 11, the company will host a fireside chat at 2:30 PM ET, providing insights into its innovative research and development.

Details of the Conference

The Guggenheim Securities conference serves as a crucial platform for InflaRx to engage with investors and share advancements in its therapeutic initiatives. During the event, InflaRx will also conduct one-on-one meetings with potential investors, facilitating deeper discussions on its strategic plans and innovations.

Live Streaming Options

For those interested in the developments at InflaRx, there will be a live stream available for the fireside chat. Attending virtually allows viewing the latest insights regarding anti-inflammatory therapies without geographic constraints.

Focus on Anti-Inflammatory Therapies

InflaRx is at the forefront of discovering and commercializing unique anti-inflammatory therapeutics, particularly by leveraging its proprietary technologies targeting the complement system. Their flagship product, vilobelimab, is an innovative drug developed to combat severe inflammatory responses. It works as a monoclonal antibody that specifically binds to C5a, a critical component in the inflammatory pathway, effectively inhibiting its function.

Recent Developments and Offerings

Beyond vilobelimab, InflaRx is advancing the development of INF904, an oral small molecule that inhibits C5a receptor signaling. These innovations play a vital role in addressing a spectrum of inflammatory conditions, highlighting InflaRx's commitment to enhancing patient outcomes.

About InflaRx N.V.

Founded in 2007, InflaRx has emerged as a leader in the biopharmaceutical landscape, focusing on targeting the complement system to address various inflammatory diseases. The company operates internationally, maintaining offices and subsidiaries in Jena and Munich, Germany, along with operations in Ann Arbor, MI. This diverse geographical spread mirrors its growing influence in the therapeutic area.

Contact Information

If you have inquiries about InflaRx, reach out to:
InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de

MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752

Frequently Asked Questions

What is the purpose of InflaRx's participation in the conference?

InflaRx aims to showcase its latest developments in anti-inflammatory therapeutics and engage with potential investors.

When will InflaRx’s fireside chat occur?

The fireside chat is scheduled for November 11 at 2:30 PM ET.

What are InflaRx’s main products?

InflaRx specializes in vilobelimab, a monoclonal antibody targeting C5a, and INF904, an oral small molecule inhibitor.

Where are InflaRx's offices located?

InflaRx has offices in Jena and Munich, Germany, and Ann Arbor, MI, USA.

How can I stream the fireside chat?

A link will be available for those interested to view the fireside chat live, offering insights into InflaRx's innovations.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.